Biogen Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹29.0K Cr
- Growth products generated $851 million in Q1 2026, up 12% YoY, underpinning positive momentum. - Biogen expects continued top-line and bottom-line growth aligned with immunology and rare disease strategies, further bolstered by the Apellis acquisition.
From Biogen Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹196.39
Market Cap
₹29.0K Cr
P/E Ratio
20.8
Revenue Rank
Margin Rank
How does Biogen Inc. rank in Biotechnology?
Compare Biogen Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Growth products generated $851 million in Q1 2026, up 12% YoY, underpinning positive momentum.
- →LEQEMBI market revenue rose 74% YoY to $168 million in Q1 2026, with strong growth in U.S., Japan, and China.
- →SKYCLARYS revenue grew 22% YoY to $151 million globally, with expansion expected mainly outside the U.S.
- →Anticipated meaningful contributions from Syfovre and Empaveli post-Apellis acquisition, enhancing top-line growth near and long term.
- →Ongoing investments in late-stage pipeline programs (felzartamab, litifilimab, Salanersen) expected to boost future revenues.
- →Multiple registrational data readouts planned over next 18 months, likely driving growth.
- →Confident outlook on expanding in China through new rights acquisitions like felzartamab.
- →Focused on disciplined cost management to support growth investments.
- →Expects commercial launches and increased patient uptake to support revenue growth.
📈 Profitability & Margins
Rank 3- →Biogen expects continued top-line and bottom-line growth aligned with immunology and rare disease strategies, further bolstered by the Apellis acquisition.
- →The Apellis transaction is anticipated to be accretive to non-GAAP EPS starting in 2027.
- →Estimated impact from Apellis deal on non-GAAP and other income/expense in 2026 is approximately $120-$130 million, mainly due to financing and foregone interest.
- →The company plans to repay new borrowings (from acquisition financing) by end of 2027 due to strong cash flow.
- →Growth products revenue increased 12% year-over-year with strong pipeline data readouts expected through the end of the decade, driving multiyear registrational data flow.
- →Investments continue in commercial and R&D efforts, including expanded nephrology portfolio through felzartamab rights acquisition.
- →Biogen's EPS outlook materially increases over the next few years due to product launches and pipeline progression.
🏗️ Capital Expenditure Plans
Yes- →Biogen plans disciplined spending to support programs in its pipeline, including investments through business development (Page 5).
- →The acquisition of Apellis is expected to close in Q2 2026, funded by $3.6 billion cash and $2 billion bank borrowings, with plans to repay borrowings by end of 2027 (Page 5).
- →Investments include prelaunch activities supporting lupus and nephrology and direct-to-consumer advertising for VUMERITY and ZURZUVAE (Page 4).
- →Biogen is building capacity through its commercial and patient services infrastructure, as highlighted in integration plans for Apellis products (Page 10).
- →Focus on early-stage development and research, including strengthening immunology pipeline through collaborations (Page 7).
- →Opportunistic M&A approach planned, with no immediate proactive search beyond recent transactions (Page 7).
💰 Fundraising & Capital Structure
No information- →Biogen plans to fund the Apellis transaction expected to close in Q2 2026 with $3.6 billion of cash and $2 billion from bank borrowings.
- →The company expects to repay the $2 billion in new borrowings by the end of 2027, indicating no long-term increase in debt.
- →No new equity fundraising is mentioned in the provided text.
- →The strong cash flow generation ($594 million free cash flow in Q1 2026) supports funding needs and deleveraging goals.
- →Biogen expects the Apellis transaction to be accretive to non-GAAP EPS in 2027, enhancing financial position.
- →Overall, the company shows discipline on costs and prioritizes existing cash and borrowing capacity over new fundraising at this time.
📋 Order Book & Pipeline
No information- →The call transcript does not explicitly mention current, expected orderbook, or pending orders figures.
- →However, it highlights strong commercial performance, with growth products generating $851 million in Q1 2026 revenue, up 12% year-over-year.
- →Specific uptake noted for products like LEQEMBI, SKYCLARYS, and SPINRAZA with growth in patient demand globally.
- →Emphasis on market growth especially outside the U.S., e.g., SKYCLARYS availability in 35 countries and LEQEMBI leading market share in U.S., Japan, and China.
- →The Apellis transaction, expected to close in Q2 2026, is anticipated to enhance top-line growth with products SYFOVRE and EMPAVELI.
- →Overall, robust demand and sequential growth imply a healthy and expanding order pipeline though exact orderbook numbers are not disclosed.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Frequently Asked Questions
What were Biogen Inc. Q2 FY26 results?
- Growth products generated $851 million in Q1 2026, up 12% YoY, underpinning positive momentum. - Biogen expects continued top-line and bottom-line growth aligned with immunology and rare disease strategies, further bolstered by the Apellis acquisition.
What is Biogen Inc. share price analysis?
Biogen Inc. currently shows a below-average growth signal. The stock trades at a P/E of 20.8 with a market cap of $28,994. Investors should review the full earnings analysis for detailed insights.
Is Biogen Inc. planning capital expenditure?
- Biogen plans disciplined spending to support programs in its pipeline, including investments through business development (Page 5).
Keep Biogen Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.